RT Journal Article
SR Electronic
T1 Description and Evaluation of a Delivery System for Aerosolized Prostacyclin
JF Respiratory Care
FD American Association for Respiratory Care
SP 742
OP 753
VO 48
IS 8
A1 Siobal, Mark S
A1 Kallet, Richard H
A1 Pittet, Jean-François
A1 Warnecke, Edna L
A1 Kraemer, Roger W
A1 Venkayya, Rajeev V
A1 Tang, Julin F
YR 2003
UL http://rc.rcjournal.com/content/48/8/742.abstract
AB INTRODUCTION: Inhaled vasodilators such as nitric oxide and aerosolized prostacyclin (PGI2) are used to treat severe hypoxemia in acute respiratory distress syndrome. Preferential distribution of nitric oxide and PGI2 to ventilated areas of the lung causes selective pulmonary vasodilation, improved ventilation/perfusion matching, and decreased hypoxemia. Because of the technical limitations of previously described methods, we developed a PGI2 delivery technique that allows the aerosolized drug dose to be easily calculated, set, and adjusted. METHODS: A 50 mL solution of PGI2 (3.0×104 ng/mL) and a 500 mL normal saline solution were infused by a dual-channel volumetric infusion pump into a MiniHEART jet nebulizer that has a manufacturer-specified output of 8 mL/h at a set flow of 2 L/min. By adjusting the pump infusion rate to achieve a total output of 8 mL/h, the PGI2 concentration was altered to deliver a calculated aerosolized dose of 10-50 ng/kg/min. The effectiveness of the delivery system was retrospectively evaluated by way of the responses of 11 severely hypoxemic acute respiratory distress syndrome patients who received PGI2 via the system we describe. The MiniHEART nebulizer output, particle size, and dose delivery were evaluated in a laboratory bench study, using a set flow of 2 L/min. RESULTS: Aerosolized PGI2 therapy (mean dose 28 ± 17 ng/kg/min, range 10–50 ng/kg/min) significantly increased the ratio of PaO2 to fraction of inspired oxygen (PaO2/FIO2) (60 ± 11 mm Hg vs 80 ± 17 mm Hg, p = 0.003) and arterial oxygen saturation measured via pulse oximetry (86 ± 8% vs 94 ± 3%, p = 0.005) (differences evaluated with the Wilcoxon signed rank test). There was no difference in positive end-expiratory pressure, mean airway pressure, or FIO2, before and after aerosolized PGI2 (p > 0.05). Nebulizer output was 6.8 ± 0.9 mL/h, range 6.0–7.8 mL/h. The inhaled aerosol particles had a mass median diameter of 3.1 μm. Emitted dose was 67 ± 13% (range 57–81%) of the calculated dose. CONCLUSION: Our system is effective in delivering aerosolized PGI2 to the alveolar-capillary interface, as indicated by significant oxygenation improvements soon after therapy commenced. The performance of the MiniHEART nebulizer varies from the manufacturer's specifications, which may alter the delivered dose.